See Bull Run's live company pages for Zydus Lifesciences and Cipla. Investors can also compare these companies with Bull Run's Zydus Lifesciences vs Lupin and Cipla vs Lupin analyses.

Q1 FY27 scorecard

The first adjustment: Zydus's ₹8,017 crore is not all pharma formulations

Subtracting the Consumer Wellness contribution gives an approximate remainder of ₹6,588 crore across Zydus's pharmaceutical and other life-sciences operations before considering detailed segment eliminations.

That is not a formally reported standalone pharma-revenue figure.

But it demonstrates why revenue composition matters.

Cipla's operating structure remains much more concentrated in pharmaceutical and related products.

The India comparison strongly favours Cipla

Cipla's broad India business was approximately 90% larger.

This is an enormous difference for two companies with virtually identical market capitalisations.

Cipla's One-India business includes:

• branded prescription medicines;
• trade generics;
• Consumer Health.

Zydus's ₹1,816 crore figure relates specifically to India formulations, so the categories are not perfectly identical.

Even allowing for classification differences, Cipla clearly owns the larger domestic pharmaceutical franchise.

Cipla's India business grew 12%

The quarter delivered the highest One-India revenue in company history.

Cipla's branded prescription portfolio grew approximately 15.4% under company-cited IQVIA market data.

Its key therapy performance included strong growth across:

• respiratory;
• urology;
• anti-diabetes;
• cardiac;
• dermatology.

This supports the view that domestic growth is broad rather than dependent on one brand.

Cipla's chronic mix reached 60.4%

Chronic therapies now represent more than three-fifths of Cipla's branded prescription portfolio.

This matters because chronic medicines create recurring demand.

Patients with asthma, COPD, diabetes, hypertension or cardiac conditions may remain on therapy for years.

That generally creates greater prescription durability than short-course acute treatments.

Respiratory remains Cipla's defining moat

Cipla is deeply embedded across India's respiratory market.

The Foracort franchise remains one of the country's major pharmaceutical brands.

Its respiratory expertise extends beyond commercial relationships.

The company has built capabilities across:

• inhalation formulation;
• device engineering;
• metered-dose inhalers;
• dry-powder inhalers;
• regulatory equivalence;
• large-scale inhaler manufacturing.

This makes respiratory a technology moat as well as a brand moat.

Zydus's India business grew much faster

Zydus India formulations increased approximately 20% to ₹1,816 crore.

That growth exceeded Cipla's 12% One-India growth.

Zydus reported strength across:

• cardiology;
• diabetology;
• gynaecology;
• anti-infectives;
• pain;
• oncology;
• nephrology.

So Cipla leads in absolute India scale.

Zydus currently leads on percentage growth.

Zydus also owns an important India innovation advantage

Zydus develops proprietary medicines and then sometimes uses external pharmaceutical partners to expand distribution.

Saroglitazar is the clearest example.

The molecule was discovered and developed by Zydus.

It is commercialised in India while also being advanced internationally.

This gives Zydus intellectual-property economics that conventional branded-generics franchises generally do not possess.

North America reverses the entire comparison

Zydus's North America revenue was therefore roughly twice Cipla's.

North America represented about 40% of Zydus consolidated revenue.

Cipla North America represented approximately 22% of consolidated revenue.

The geographic risk structure is therefore very different.

Zydus North America revenue declined only modestly

Revenue declined approximately 3% year on year but improved sequentially.

The company continues evolving its US mix toward:

• branded specialty products;
• orphan medicines;
• 505(b)(2) products;
• biosimilars;
• internally developed innovation.

This is strategically important because conventional generic pricing can erode rapidly.

Cipla North America experienced a much sharper reset

Cipla's Q1 North America revenue was approximately US$162 million.

The comparable quarter had benefited from significantly stronger lenalidomide and lanreotide economics.

As those contributions normalized, revenue and margin declined.

This is the main reason Cipla's Q1 consolidated growth looked weak despite record Indian sales.

Cipla's US business is rebuilding around differentiated products

Cipla launched its first AB-rated generic Ventolin inhaler during Q1.

It has supplied more than 50 million inhaler units cumulatively into the US market.

Its albuterol franchise has achieved strong market share.

Other newer products include differentiated respiratory, oncology, peptide and metabolic assets.

That creates the core Cipla recovery thesis

Cipla does not need its India business to accelerate from 12% to 25% growth.

It needs North America profitability to normalize.

If new respiratory and other differentiated products replace part of the lost high-margin contribution, EBITDA can recover much faster than consolidated revenue.

That creates substantial operating leverage from today's depressed margin base.

Zydus has a different US catalyst: proprietary specialty medicine

This is fundamentally different from another generic approval.

Saroglitazar is an internally developed molecule.

If approved and commercially successful, Zydus would participate in branded specialty-drug economics.

The company has said it is building commercial capabilities around a potential US launch.

Priority Review does not mean approval is guaranteed

The FDA's Priority Review designation accelerates regulatory review for potentially important medicines.

It does not guarantee a positive decision.

The relevant risks include:

• regulatory review;
• label scope;
• commercial execution;
• payer coverage;
• competitive therapies;
• physician adoption.

The November date should therefore be treated as a catalyst, not a certainty.

Zydus's Phase 3 results create a credible clinical foundation

The EPICS-III Phase 3 trial met its primary biochemical-response endpoint.

Zydus reported a substantially higher response rate in treated patients than placebo.

That is why Saroglitazar matters so much strategically.

It is a visible test of whether an Indian pharmaceutical company can convert internal discovery into a meaningful US branded product.

Zydus already has other US specialty assets

The company's strategy includes increasing branded products within North America.

Acquisitions and internal development give it exposure beyond conventional generics.

The objective is to create a more durable US revenue mix where fewer products are exposed to immediate commodity price erosion.

Zydus has another major business Cipla does not: Consumer Wellness

Consumer Wellness generated approximately ₹1,429 crore of Q1 revenue.

This includes consumer-facing categories with different economics from prescription medicines.

That diversification can reduce dependence on pharmaceutical product cycles.

It also complicates direct margin comparisons.

Consumer businesses create different advantages

A strong consumer brand can create:

• direct customer recognition;
• retail distribution power;
• repeat purchase behaviour;
• lower regulatory binary risk than a drug pipeline.

But consumer businesses require marketing expenditure and can be exposed to commodity inflation.

Their margins may differ materially from high-value pharmaceutical products.

Zydus's Q1 EBITDA margin fell despite strong revenue growth

EBITDA declined approximately 8% to ₹1,929 crore.

Margin fell from approximately 31.8% to 24.1%.

PAT declined approximately 36%.

This shows headline 22% revenue growth did not translate into earnings growth.

Why did Zydus's profit conversion weaken?

The company is carrying a broader mix of:

• Consumer Wellness;
• specialty investment;
• acquisition-related costs;
• higher employee expenses;
• higher finance costs;
• R&D investment.

The question is whether these investments produce a stronger future earnings base.

Cipla's margin was even weaker

EBITDA fell approximately 33% to ₹1,192 crore.

North America mix was a major reason.

Launch expenditure and quarter-specific operating costs also affected profitability.

Cipla continues to expect stronger profitability than Q1 over a full-year cycle.

Zydus therefore wins the reported margin comparison

24.1% versus 16.7% is a large gap.

But both companies were operating below their respective prior-year margins.

The better investment question is not which margin was higher in Q1.

It is which company can rebuild or expand margin more sustainably.

R&D spending is higher at Zydus

Zydus invested approximately ₹642 crore during Q1.

That represented around 8% of revenue.

Cipla invested approximately ₹486 crore, or 6.8%.

Zydus therefore spent more both absolutely and proportionally.

The R&D strategies are different

Zydus is funding:

• novel medicines;
• specialty drugs;
• biosimilars;
• complex generics;
• branded US products.

Cipla focuses significantly on:

• respiratory;
• complex generics;
• peptides;
• inhalation assets;
• selected specialty opportunities.

Zydus therefore accepts more proprietary-drug development risk.

Cipla has the cleaner balance sheet

Balance-sheet flexibility matters in pharma

Drug pipelines are uncertain.

Companies often need to fund:

• clinical development;
• licensing payments;
• manufacturing plants;
• working capital;
• acquisitions;
• commercial launches.

Cipla can currently fund many of these investments without increasing financial leverage.

Zydus's debt is tied to a broader strategic expansion

Zydus has used capital for acquisitions and new capabilities.

That can create long-term value if branded specialty and consumer assets generate adequate returns.

The correct measure is therefore future ROCE, not simply whether debt exists.

Current ROCE actually favours Zydus

Zydus generates higher current percentage returns.

Cipla has generated much more cumulative five-year free cash flow.

This is another illustration of current-cycle profitability versus long-term cash history.

The market-cap comparison is almost perfectly balanced

Bull Run currently records Zydus market capitalisation at approximately ₹1.154 lakh crore.

Cipla is approximately ₹1.161 lakh crore.

The difference is less than 1%.

Investors are therefore allocating essentially the same market value to either company.

But the current earnings multiples are not the same

Zydus trades at a substantially lower trailing earnings multiple.

It also generates higher current ROCE.

On those two metrics alone, Zydus appears clearly cheaper.

Why does Cipla still command the higher P/E?

The market likely expects its current earnings to recover.

Q1 reflects an unusually weak North America product cycle.

If US respiratory and other differentiated launches scale, EBITDA can rebound without requiring huge additional capital.

Cipla also has a large India franchise and net cash, which supports earnings durability.

Why does Zydus trade at the higher price-to-book multiple?

Zydus's current ROE is substantially higher.

The market therefore pays more for each rupee of Zydus book value.

This is economically reasonable if higher returns persist.

If acquisition investment reduces ROE over time, that premium can compress.

Recent share-price momentum favours Zydus

Bull Run's current one-year return is approximately:

• Zydus: +15.9%;
• Cipla: -10.0%.

This means Zydus has already enjoyed stronger investor sentiment.

Yet its P/E remains lower because earnings are still larger relative to market value.

What must Zydus prove?

• Saroglitazar must navigate FDA review successfully.
• US branded products need continued scaling.
• India formulations should maintain strong double-digit growth.
• Q1 margin compression should reverse or stabilise.
• Consumer Wellness needs attractive returns on invested capital.
• Acquisition leverage should remain controlled.
• R&D spending must create commercially meaningful products.

What must Cipla prove?

• North America revenue needs sequential recovery.
• New respiratory launches need meaningful market share.
• EBITDA margin must recover from 16.7%.
• India should sustain double-digit growth.
• Chronic share should remain strong.
• Large net cash must be allocated productively.
• US manufacturing and regulatory compliance must remain disciplined.

What could make Zydus outperform Cipla?

A successful specialty-drug transition.

If Saroglitazar receives approval and Zydus continues shifting its US portfolio toward branded products, the company can generate more durable margins than a conventional generic-heavy business.

Its lower current P/E gives additional support.

What could make Cipla outperform Zydus?

A North America earnings recovery from a depressed base.

Cipla already has India's much larger franchise.

If US revenue and margins recover while India continues compounding, the company can add a second growth engine without taking the same proprietary-drug clinical risk as Zydus.

Which has the stronger India franchise?

Cipla by a wide margin on absolute Q1 revenue.

One-India generated ₹3,452 crore versus Zydus India formulations at ₹1,816 crore.

Which has stronger India growth?

Zydus.

Its India formulations grew approximately 20% versus Cipla's broad One-India growth of around 12%.

Which has the stronger North America business?

Zydus by current revenue.

North America formulations generated approximately US$327 million versus Cipla at US$162 million.

Which has the stronger respiratory franchise?

Cipla.

Respiratory is one of its defining commercial and technological capabilities in both India and the United States.

Which has the stronger innovation catalyst?

Zydus.

Saroglitazar's November 27, 2026 FDA target action date creates a clearly identifiable proprietary-drug catalyst.

Which has the stronger balance sheet?

Cipla.

It holds approximately ₹9,494 crore net cash, while Zydus carries manageable but meaningful acquisition-related leverage.

Which stock has the stronger current valuation?

Zydus on earnings and ROCE.

It trades at approximately 25.6x P/E versus Cipla around 34.5x while earning materially higher current ROCE.

Which is better: Zydus Lifesciences or Cipla?

Zydus currently has the stronger valuation-adjusted reported operating profile. It generated higher Q1 EBITDA and PAT, has twice Cipla's current North America revenue, earns higher ROCE and trades at a lower trailing P/E.

Cipla has the stronger domestic-pharma and balance-sheet profile. Its India business is almost twice Zydus's formulations business by quarterly revenue, respiratory remains a major moat, and approximately ₹9,494 crore net cash gives it exceptional financial flexibility.

There is also an important normalization issue.

Zydus's headline revenue includes a large Consumer Wellness business.

Cipla's current Q1 earnings are unusually depressed by the North America cycle.

At September 2026 valuations, Zydus offers stronger current earnings and a lower P/E, plus proprietary specialty upside. Cipla becomes more attractive if its US respiratory pipeline restores margins, because its Indian franchise and net-cash balance sheet provide a much stronger earnings floor than the Q1 headline numbers suggest.

Frequently asked questions